% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Benzarti:143405,
      author       = {S. Benzarti and M. Daskalakis and A. Feller and V. U.
                      Bacher and A. Schnegg-Kaufmann and A. Rüfer and A. Holbro
                      and A. Schmidt and R. Benz and M. Solenthaler and G. Stussi
                      and V. Arndt$^*$ and N. Bonadies},
      collaboration = {N. W. Group},
      title        = {{T}rends of incidence and survival of patients with chronic
                      myelomonocytic leukemia between 1999 and 2014: {A}
                      comparison between {S}wiss and {A}merican population-based
                      cancer registries.},
      journal      = {Cancer epidemiology},
      volume       = {59},
      issn         = {1877-7821},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2019-00993},
      pages        = {51 - 57},
      year         = {2019},
      abstract     = {Chronic myelomonocytic leukemia (CMML) is a rare
                      hematopoietic malignancy. Treatment with hypomethylating
                      agents (HMA) was introduced between 2004 and 2006 but its
                      impact on population-based survival remains controversial.
                      The aim of this study was to investigate epidemiological
                      characteristics and survival before and after introduction
                      of HMA treatment.We performed a population-based analysis of
                      CMML cases reported to the Cantonal Cancer Registries in
                      Switzerland (SWISS) and the Surveillance, Epidemiology, and
                      End Results (SEER) Program from the United States for
                      1999-2006 (before HMA) and 2007-2014 (after HMA). Time
                      trends were compared for these two time periods.423 and 4144
                      new CMML cases were reported to the SWISS and SEER
                      registries, respectively. We observed an increasing
                      proportion of older patients ≥75 years in the SWISS
                      $(50.3\%-62.3\%)$ compared to a decreasing one in the SEER
                      population $(59.1\%-55.1\%).$ Age standardized
                      incidence-rates were similar and remained stable in both
                      countries (0.32-0.38 per 100'000 py). Relative survival (RS)
                      improved significantly in the SEER (3 years $27\%-37\%;$ 5
                      years $19\%-23\%;$ p < 0.001 for both) but remained
                      stable in the SWISS population (3 years $48\%$ to $40\%;$ 5
                      years $34\%$ to $26\%;$ n.s. for both).With the exception of
                      opposing age-trends, epidemiologic characteristics are
                      similar in both countries and comparable to other
                      population-based registries. RS remains poor and different
                      time trends of population-based survival cannot be
                      faithfully explained by HMA but most likely by changes in
                      diagnostic accuracy within prognostically distinct
                      age-groups.},
      cin          = {C071},
      ddc          = {610},
      cid          = {I:(DE-He78)C071-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30690330},
      doi          = {10.1016/j.canep.2019.01.003},
      url          = {https://inrepo02.dkfz.de/record/143405},
}